Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.75 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2615420 | 1.00 | SLC6A4 (0.75) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| O-Desmethyl Tramadol SCHEMBL2517055 | 0.86 | OPRM1 (1.00) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| Desmetramadol SCHEMBL57246 | 0.86 | OPRM1 (1.00) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| O-Desmethyl Tramadol SCHEMBL4396389 | 0.86 | OPRM1 (1.00) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| O-Desmethyl Tramadol SCHEMBL4396391 | 0.86 | OPRM1 (1.00) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| SCHEMBL7921501 | 0.86 | SLC6A4 (0.77) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| Desmetramadol SCHEMBL12125413 | 0.86 | OPRM1 (1.00) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| O-Desmethyl Tramadol SCHEMBL7882257 | 0.85 | OPRM1 (0.97) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| Desmetramadol SCHEMBL2410234 | 0.85 | OPRM1 (0.97) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6944014 | 0.85 | SLC6A4 (0.75) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095217-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095217-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | FLI1, CDC73, FOS | SLC6A4 916/4885SLC6A2 957/4885OPRM1 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.